Viewing Study NCT05635734


Ignite Creation Date: 2025-12-25 @ 2:28 AM
Ignite Modification Date: 2025-12-25 @ 2:28 AM
Study NCT ID: NCT05635734
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-11-18
First Post: 2022-11-23
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
Sponsor: Cantex Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module